Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(165 productos)
- Bcr-Abl(117 productos)
- EGFR(561 productos)
- FAK(72 productos)
- FLT(89 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(177 productos)
- JAK(243 productos)
- PDGFR(127 productos)
- RAAS(86 productos)
- Src(82 productos)
- Syk(37 productos)
- Trombina(51 productos)
- VDA(2 productos)
- VEGFR(239 productos)
Mostrar 6 subcategorías más
Se han encontrado 2260 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
VEGFR-2-IN-18
VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.Fórmula:C20H13ClN4O2Forma y color:SolidPeso molecular:376.8mG2N001
CAS:mG2N001, a negative allosteric modulator (NAM) of the metabotropic glutamate receptor mGluR2, has an IC50 of 93 nM and binds to mGluR2 as an antagonist with a Ki of 63 nM. This compound is microparticle- and plasma-stable, and its radioisotope [11C] mG2N001 can be utilized in PET imaging. [11C] mG2N001 exhibits good brain heterogeneity and penetration, selectively accumulating in mGluR2-rich regions to produce high-contrast brain images [1].Fórmula:C18H19FN2O3Forma y color:SolidPeso molecular:330.35GLPG3312
CAS:GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Fórmula:C23H21F2N5O3Pureza:98.53%Forma y color:SolidPeso molecular:453.44EGFR-IN-47
EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.Fórmula:C29H35N7Forma y color:SolidPeso molecular:481.64FGFR1 inhibitor-15
CAS:FGFR1inhibitor-15 (Compound 23) is an FGFR1 inhibitor with an IC50 value of 27 μM, useful for tumor research.Fórmula:C17H13FN4OForma y color:SolidPeso molecular:308.31FGFR1 inhibitor-16
CAS:FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.Fórmula:C16H9N5O3SForma y color:SolidPeso molecular:351.339FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Fórmula:C28H30N4O2Forma y color:SolidPeso molecular:454.56BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Fórmula:C35H35ClN4O3SForma y color:SolidPeso molecular:627.2EGFR-IN-3
EGFR-IN-3 is an EGFR inhibitor with antitumor activity.EGFR-IN-3 inhibits EGFRwt-TK, induces apoptosis (cell death), and can block cells in the G2/M phase.Fórmula:C24H18F4N6O2SPureza:98.1%Forma y color:SolidPeso molecular:530.5VEGFR-2-IN-14
VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Fórmula:C24H23N3O3SForma y color:SolidPeso molecular:433.52EGFR-IN-133
CAS:EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.Fórmula:C27H29F2N7O3Forma y color:SolidPeso molecular:537.56EGFR-IN-45
EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.Fórmula:C28H23N7OForma y color:SolidPeso molecular:473.53HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Fórmula:C28H26F3N7O3Forma y color:SolidPeso molecular:565.55(R)-9b
CAS:(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.Fórmula:C20H27ClN6OForma y color:SolidPeso molecular:402.92VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Fórmula:C22H24N6O3SForma y color:SolidPeso molecular:452.53DA-0157
CAS:DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Fórmula:C31H43BrN7O2PForma y color:SolidPeso molecular:656.597Milpecitinib
CAS:Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.
Fórmula:C20H20N4O2SForma y color:SolidPeso molecular:380.463Tesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Fórmula:C31H33Cl2FN4O5SForma y color:SolidPeso molecular:663.59BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Fórmula:C29H33ClN8O4Forma y color:SolidPeso molecular:593.08YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Fórmula:C32H34F3N7O2Forma y color:SolidPeso molecular:605.65
